0000950170-23-030757.txt : 20230629
0000950170-23-030757.hdr.sgml : 20230629
20230629161652
ACCESSION NUMBER: 0000950170-23-030757
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230627
FILED AS OF DATE: 20230629
DATE AS OF CHANGE: 20230629
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Haviland Kate
CENTRAL INDEX KEY: 0001663022
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38978
FILM NUMBER: 231057599
MAIL ADDRESS:
STREET 1: BLUEPRINT MEDICINES CORPORATION
STREET 2: 38 SIDNEY STREET, SUITE 200
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc.
CENTRAL INDEX KEY: 0001680581
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474839948
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-651-8851
MAIL ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
ownership.xml
4
X0407
4
2023-06-27
false
0001680581
Fulcrum Therapeutics, Inc.
FULC
0001663022
Haviland Kate
C/O FULCRUM THERAPEUTICS, INC.
26 LANDSDOWNE STREET
CAMBRIDGE
MA
02139
true
false
false
false
false
Stock Option (right to buy)
3.16
2023-06-27
4
A
false
30000
0.00
A
2033-06-26
Common Stock
30000
30000
D
This option was granted on June 27, 2023 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
/s/ Greg Tourangeau, as attorney-in-fact for Kate Haviland
2023-06-29